357 filings
Page 5 of 18
8-K
p5puzsbus
26 Nov 18
ImmunoGen Announces Resignation of Chief Financial Officer
4:15pm
8-K
k0d4darsjjw7jv8lzcf
2 Nov 18
ImmunoGen Reports Recent Progress and Third Quarter 2018 Operating Results
6:36am
8-K
z2cv87 7cdggu
27 Jul 18
ImmunoGen Reports Recent Progress and Second Quarter 2018 Operating Results
6:35am
8-K
6wi3sx6v
28 Jun 18
Entry into a Material Definitive Agreement
4:05pm
8-K
2bqgtxxf8l 0mymau
22 Jun 18
Departure of Directors or Certain Officers
4:02pm
8-K
f29kbv802j uarzz3ij
21 Jun 18
ImmunoGen Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
8:27am
8-K
8y608m8rzl
11 Jun 18
ImmunoGen Announces Closing of Public Offering of Common Stock
4:13pm
8-K
163q7l9q
7 Jun 18
Entry into a Material Definitive Agreement
4:35pm
8-K
4srlt 1zii
17 May 18
Data from Avastin Cohort to be Presented at 2018 ASCO Annual Meeting
7:50am
8-K
cawwuxt skot
4 May 18
ImmunoGen Reports Recent Progress and First Quarter 2018 Operating Results
6:36am
8-K
k9ukczymr
26 Apr 18
FORWARD I trial has completed full enrolloment; top-line results expected in the first half of 2019
12:00am
8-K
c1gkl5rj
9 Apr 18
Entry into a Material Definitive Agreement
12:00am
8-K
ilp4n 75b35
30 Mar 18
Entry into a Material Definitive Agreement
12:00am
8-K
kz419i37lea8lw zek97
20 Feb 18
Departure of Directors or Certain Officers
12:00am
8-K
7q0t87 zw
9 Feb 18
ImmunoGen Reports Pipeline Progress and 2017 Operating Results
12:00am
8-K
70fe35
8 Feb 18
Cost Associated with Exit or Disposal Activities
12:00am
8-K
p21ntzyakyfply
24 Jan 18
ImmunoGen Appoints Stuart A. Arbuckle to Board of Directors
12:00am
8-K
comxrv
8 Jan 18
Results of Operations and Financial Condition
12:00am
8-K
bdfprwqa
3 Nov 17
ImmunoGen Reports Recent Progress and Third Quarter 2017 Operating Results
12:00am
8-K
b8661w245t
11 Oct 17
Immunogen Announces Closing of Public Offering
12:00am